1110002N22Rik Activators are a selection of chemical compounds that serve to increase the functional activity of 1110002N22Rik through diverse yet specific signaling mechanisms. Compounds like Forskolin and IBMX work by enhancing intracellular cAMP levels; Forskolin through direct activation of adenylyl cyclase and IBMX by inhibiting cAMP degradation, which leads to enhanced PKA signaling that could increase the phosphorylation state and thereby the activity of 1110002N22Rik. Glucokinase Activators are a diverse range of compounds that augment the functional activity of Glucokinase through various biochemical mechanisms, ensuring efficient glucose metabolism in cells. The most direct activators are the substrates of Glucokinase themselves, with glucose acting as the primary molecule whose increased concentration directly enhances enzyme activity through substrate saturation. Mannose and ATP serve similar roles, with mannose being an alternative substrate and ATP providing the necessary phosphate group for the enzymatic reaction.
Fructose-1-phosphate and fructose-6-phosphate act as allosteric enhancers; the former increases the substrate affinity of Glucokinase, while the latter inhibits the regulatory protein that modulates Glucokinase's activity, thereby increasing its cytoplasmic availability and functional state. Further indirect activators include metabolic intermediates such as sorbitol, which is converted into fructose and subsequently into fructose-1-phosphate, glyceraldehyde, which contributes to the pool of glycolytic intermediates, and inosine, which, through its metabolites, can increase levels of fructose-2,6-bisphosphate, thereby enhancing glycolytic flux and Glucokinase activity. NAD+ and essential ions like magnesium and potassium play supportive roles in maintaining Glucokinase activity; NAD+ ensures enzymatic reactions proceed efficiently, while Mg2+ stabilizes ATP and K+ optimizes enzyme conformation
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, thereby preventing the breakdown of cAMP and contributing to enhanced activation of the cAMP-dependent pathway that indirectly activates 1110002N22Rik. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C (PKC), which may lead to phosphorylation events that enhance the activity of 1110002N22Rik through downstream signaling pathways. | ||||||
Sodium Fluoride | 7681-49-4 | sc-24988A sc-24988 sc-24988B | 5 g 100 g 500 g | $40.00 $46.00 $100.00 | 26 | |
Sodium fluoride acts as a nonspecific activator of guanylyl cyclase, increasing cGMP levels, which can indirectly activate cGMP-dependent protein kinases influencing the signaling pathways associated with 1110002N22Rik activation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels, potentially enhancing the activity of 1110002N22Rik through calcium-dependent signaling pathways and kinases like calmodulin-dependent kinase. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterase type 5, leading to an increase in cGMP levels which may enhance the functional activity of 1110002N22Rik through the cGMP-dependent kinase pathway. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase type 4, which results in increased cAMP levels, thereby potentially enhancing 1110002N22Rik activity through cAMP-dependent PKA signaling. | ||||||
YC-1 | 170632-47-0 | sc-202856 sc-202856A sc-202856B sc-202856C | 1 mg 5 mg 10 mg 50 mg | $33.00 $124.00 $218.00 $947.00 | 9 | |
YC-1 is a soluble guanylyl cyclase activator, leading to increased levels of cGMP, which could enhance the activity of 1110002N22Rik through cGMP-dependent signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that may lead to the activation of alternate pathways that compensate by enhancing the activity of 1110002N22Rik, as PI3K pathway modulation can redistribute signaling flux through interconnected networks. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can indirectly enhance the activity of 1110002N22Rik by modifying the signaling pathways that control the activity of proteins that interact with or regulate 1110002N22Rik. | ||||||